Keith A. Goldan

Keith A. Goldan (finance chief) discloses dealings in 3 companies, chiefly Syndax Pharmaceuticals Inc, OptiNose, Inc. and Abeona Therapeutics Inc. We count 18 filings; the first trade dates from 17 June 2021 and the latest from 1 April 2026.

In open-market terms, that means 2 purchases worth €23k on one side and 8 sales worth €153k on the other. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants. 2026 to date brings no purchases and 1 sale.

Most recently, on 7 April 2026, the filings show a share grant in Abeona Therapeutics Inc. The most recent open-market purchase was published on 19 May 2025, 517 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.